Liver Testing Through a New Investigative Tool
HepQuant: A minimally invasive assessment of chronic liver disease
New Investigative Tools to Evaluate the Liver
assessment of chronic liver disease
Novel technology for minimally invasive
Liver Function Tests: Breaking Through Conventional Thinking About Liver Health Testing
HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.
Greg Everson, MD, HepQuant’s Chief Executive Officer, presented at the NASH Summit 2019, April 22-25, 2019 in Boston. Dr. Everson was a key speaker during the Clinical Stream Segment entitled “Strategic Considerations for Phase 3 Clinical Trials,” on Tue., April 23rd.
Highlights from the 2nd Annual NASH Summit – Boston | April 2018
- Apr. 4 – HepQuant’s Disease Severity Index (DSI) Demonstrates Hepatic Functional Improvement in High Percentage of NASH Patients Treated with Obeticholic Acid: Results from INTERCEPT 747-117
- Feb. 20 – Hoffman Joins HepQuant as Clinical Lab Manager
- Feb. 14 – First Patient Enrolled in a Pivotal Trial of the HepQuant SHUNT Liver Diagnostic Test
- Nov. 15 – Sarah Downing Joins HepQuant as Senior Manager of Quality Affairs
- Nov. 9 – Receives IDE Approval from U.S. FDA to Initiate Clinical Trial of the SHUNT Liver Diagnostic Kit
EASL International Liver Congress: Greg Everson, MD, and Brad Everson, HepQuant’s CEO and CBDO respectively, attended the EASL International Liver Congress, April 10-14, 2019 in Vienna, Austria.
Poster: A late breaker poster was released at EASL ILC 2019 discussing baseline and Day 85 HepQuant-SHUNT™ and Disease Severity Index (DSI) results from Intercept study 747-117 conducted in parallel to the Regenerate study. “Effect of Obeticholic Acid on Liver Function in Patients With Fibrosis due to NASH.” Naim Alkhouri (1), Gregory T. Everson (2), Steve Helmke (2), Jianfen Chen (3), Carl LaCerte (3), Michael Stenkilsson (3), Jeffrey E. Edwards (3). 1 Texas Liver Institute, University of Texas Health, San Antonio, TX; 2 HepQuant, Greenwood Village, CO; 3. Intercept Pharmaceuticals, Inc., San Diego, CA.
HepQuant attended and presented posters at the 2019 NASH-TAG Conference in Park City, Utah in January 2019.
Poster: Title: “Hepatobiliary and Metabolic Changes Occurring during Weight Loss and Subsequent Weight Maintenance in Obese Subjects: Implications for NASH Clinical Trials.” Thomas E. Trouillot (1), Robert H. Eckel (1), and Gregory T. Everson (1,2). 1. University of Colorado; 2. HepQuant, LLC, Greenwood Village, CO
Poster: “Modeling the HepQuant STAT Test for Pre-screening NASH Subjects to Enrich Study Populations for the Desired Stage of Disease.” Steve M. Helmke and Gregory T. Everson HepQuant, LLC, Greenwood Village, CO.